Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;79(8):821-822.
doi: 10.1001/jamaneurol.2022.1735.

Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach

Francesca Bovis  1 , Marta Ponzano  1 , Alessio Signori  1 , Irene Schiavetti  1 , Paolo Bruzzi  1 , Maria Pia Sormani  1   2
Affiliations

Reinterpreting Clinical Trials in Children With Multiple Sclerosis Using a Bayesian Approach

Francesca Bovis et al. JAMA Neurol. .

Abstract

This systematic review and meta-analysis investigates the use of the bayesian approach to estimate the plausible effect of teriflunomide in children with multiple sclerosis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Bovis reported receiving teaching honoraria from Novartis and personal fees from Eisai, Biogen, and Chiesi outside the submitted work. Dr Sormani reported receiving personal fees from Merck, Biogen, Roche, Novartis, and Sanofi outside the submitted work. No other disclosures were reported.

Figures

Figure.
Figure.. Probability Density Functions for the Prior Distribution, the Likelihood, and the Posterior Distribution for the Teriflunomide Effect in Children
The dashed black lines represent the credible intervals bands and the dotted black line represents treatment inefficacy (hazard ratio = 1).
See this image and copyright information in PMC

References

    1. Sormani MP, Waubant E. Paediatric multiple sclerosis: a lesson from TERIKIDS. Lancet Neurol. 2021;20(12):971-973. doi:10.1016/S1474-4422(21)00372-0 - DOI - PubMed
    1. Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5(1):27-36. doi:10.1038/nrd1927 - DOI - PubMed
    1. O’Connor P, Wolinsky JS, Confavreux C, et al. ; TEMSO Trial Group . Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med. 2011;365(14):1293-1303. doi:10.1056/NEJMoa1014656 - DOI - PubMed
    1. Confavreux C, O’Connor P, Comi G, et al. ; TOWER Trial Group . Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247-256. doi:10.1016/S1474-4422(13)70308-9 - DOI - PubMed
    1. Chitnis T, Banwell B, Kappos L, et al. ; TERIKIDS Investigators . Safety and efficacy of teriflunomide in paediatric multiple sclerosis (TERIKIDS): a multicentre, double-blind, phase 3, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(12):1001-1011. doi:10.1016/S1474-4422(21)00364-1 - DOI - PubMed